Plain-English translation of NCT07509645 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called , when given alongside emergency endovascular treatment (a procedure to remove blood clots from brain vessels), can help people recover better from a specific type of stroke affecting the back of the brain. Half of the participants will receive the medication, and half will receive a placebo (inactive injection) — neither you nor the doctors will know which you're getting. The goal is to see if this medication can reduce brain damage and improve long-term outcomes.
Strokes caused by large blood clots in the back of the brain are very serious and can cause lasting disability or death. While emergency blood clot removal surgery saves lives, researchers believe this medication might reduce the inflammation that happens after a stroke and potentially improve recovery even further.
You likely qualify if…
You likely don't qualify if…
You will receive emergency endovascular treatment to remove the blood clot from your brain. During or shortly after this procedure, you will receive either a single injection of or a placebo injection as part of the study. You will be followed closely by the research team after your stroke, with follow-up visits and assessments to monitor your recovery and check for any side effects. The study aims to track your progress over several months to see how well you recover.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China